Applying the Latest Evidence to Overcome Endocrine Resistance in HR+/HER2- Breast Cancer
Webcast
0.25 AMA PRA Category 1 Credit™ ...OVERVIEW
Applying the Latest Evidence to Overcome Endocrine Resistance in HR+/HER2- Breast Cancer is organized by Prime Education, LLC.
Release Date: June 28, 2024
Expiration Date: October 3, 2025
Description:
Several important biomarkers have been uncovered in endocrine-resistant HR+/HER2- breast cancer, leading to new and emerging treatment options for these patients.
Test your knowledge of relevant biomarker assessment and agents that combat endocrine resistance in HR+/HER2- breast cancer with this bite-sized Booster Quiz. Receive immediate expert feedback and, following the quiz, download a summary of key supporting evidence.
Learning Objectives:
- Identify key biomarkers associated with new and emerging targeted therapies for the management of hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
- Apply knowledge of molecular markers to optimize therapeutic decision-making for HR+/HER2- metastatic breast cancer patients who have experienced endocrine resistance to prior therapies
- Describe the mechanisms of action of new and emerging agents that have the ability to overcome endocrine resistance for those with HR+/HER2- advanced breast cancer
- Evaluate the latest safety and efficacy data surrounding AKT inhibitors, selective estrogen receptor degraders (SERDs), phosphatidylinositol-3-kinase (PI3K) inhibitors, and antibody-drug conjugates (ADCs) for the treatment of HR+/HER2- advanced breast cancer
- Develop optimal therapeutic strategies for patients with endocrine-resistant HR+/HER2- breast cancer based on pertinent clinical trial evidence and patient-specific factors
ACCREDITATION & CREDITS
Physician Credit Designation Statement
PRIME® designates this Enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistant Accreditation Statement
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioner Accreditation Statement
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. This activity is approved for 0.25 contact hour (which includes 0.25 hour of pharmacology).
Pharmacist Accreditation Statement
This Knowledge-based activity has been approved for 0.25 contact hour (0 CEUs) by PRIME® for pharmacists. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion.
Nurse Accreditation Statement
PRIME® designates this activity for 0.25 contact hour.
TARGET AUDIENCE
PharmacistOncologistsNursesBreast CancerEndocrinologistNurse PractitionersSPECIALITIES
OncologyEndocrinology
Quick Links